Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | LMRI | IRMD |
|---|---|---|
| Price | $10.59 | $85.47 |
| Change today | ▼ 1.12% | ▲ 0.77% |
| Market cap | $1.02B | $1.09B |
| Return, 3 months | -13.1% | -12.6% |
| Return, year to date | -42.8% | -11.6% |
| Return, 1 year | – | +12.7% |
| P/E (TTM) | -36.6 | 47.7 |
| P/B | 1.7 | 10.7 |
| P/E percentile vs own 5y | 23rd | 72nd |
| Dividend yield | – | 0.87% |
| Revenue growth (YoY, latest qtr) | +5.1% | +0.3% |
| Net profit growth (YoY) | +138.0% | -9.6% |
| Gross margin | 14.9% | 75.9% |
| Operating margin | 1.4% | 31.9% |
| Net margin | -2.7% | 26.7% |
| Return on equity | -4.5% | 23.5% |
| Analyst target vs. price | +62.1% | +40.4% |
| Analyst buy share | 100% | 50% |
| RSI (14) | 46 | 49 |
| 30-day volatility | 37.1% | 22.0% |
| Max drawdown, 1 year | -63.5% | -21.8% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
